Literature DB >> 18496698

A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab.

Takeshi Kuroda1, Yasuhiro Otaki, Hiroe Sato, Takeo Fujimura, Takeshi Nakatsue, Syuichi Murakami, Minoru Sakatsume, Masaaki Nakano, Fumitake Gejyo.   

Abstract

We report the case of a 55-year-old Japanese woman with reactive AA amyloidosis associated with rheumatoid arthritis, in which inflammatory disease was completely suppressed with infliximab. Nephrotic syndrome was observed and renal biopsy specimens revealed amyloidosis deposits. Treatment with infliximab normalized the serum amyloid A (SAA) protein level, and subsequently nephritic syndrome disappeared and her creatinine clearance improved. Serial gastrointestinal biopsy specimens showed marked lasting regression of amyloid deposits. Thus treatment with infliximab represents an important therapeutic strategy for AA amyloidosis associated with RA.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18496698     DOI： 10.1007/s00296-008-0590-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  26 in total

1.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.

Authors:  S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.

Authors:  Ori Elkayam; Philip N Hawkins; Helen Lachmann; Michael Yaron; Dan Caspi
Journal:  Arthritis Rheum       Date:  2002-10

3.  The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.

Authors:  N Tanaka; H Yonekura; S Yamagishi; H Fujimori; Y Yamamoto; H Yamamoto
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

4.  Infliximab and nephrotic syndrome.

Authors:  George Chin; Grant Luxton; Jennet M Harvey
Journal:  Nephrol Dial Transplant       Date:  2005-10-04       Impact factor: 5.992

5.  Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Authors:  Najia Shakoor; Margaret Michalska; Charlotte A Harris; Joel A Block
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 6.  New approaches to modify glomerular inflammation.

Authors:  D C Kluth; A J Rees
Journal:  J Nephrol       Date:  1999 Mar-Apr       Impact factor: 3.902

7.  Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Takashi Harada; Syuichi Murakami; Hisashi Hasegawa; Minoru Sakatsume; Masaaki Nakano; Fumitake Gejyo
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

8.  Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis.

Authors:  G R Smith; K E Tymms; M Falk
Journal:  Intern Med J       Date:  2004 Sep-Oct       Impact factor: 2.048

9.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors:  Jacques-Eric Gottenberg; Florence Merle-Vincent; Fabrice Bentaberry; Yannick Allanore; Francis Berenbaum; Bruno Fautrel; Bernard Combe; Antoine Durbach; Jean Sibilia; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2003-07

10.  Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency.

Authors:  M Ahlmen; J Ahlmen; C Svalander; H Bucht
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980
View more
  12 in total

1.  A case report on nephrotic syndrome associated with ankylosing spondylitis effectively treated with infliximab.

Authors:  Xin Feng; Yao Li; Wei Gao
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 2.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

3.  A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept.

Authors:  Wataru Ishii; Dai Kishida; Ayako Suzuki; Yasuhiro Shimojima; Masayuki Matsuda; Yoshinobu Hoshii; Shu-Ichi Ikeda
Journal:  Rheumatol Int       Date:  2009-10-10       Impact factor: 2.631

4.  Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.

Authors:  Hiroe Sato; Takehito Sakai; Toshiaki Sugaya; Yasuhiro Otaki; Kana Aoki; Katsushi Ishii; Hidehiro Horizono; Hiroshi Otani; Asami Abe; Noboru Yamada; Hajime Ishikawa; Kiyoshi Nakazono; Akira Murasawa; Fumitake Gejyo
Journal:  Clin Rheumatol       Date:  2009-05-13       Impact factor: 2.980

5.  A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.

Authors:  Ömer Nuri Pamuk; Umut Kalyoncu; Kenan Aksu; Ahmet Omma; Yavuz Pehlivan; Yonca Çağatay; Orhan Küçükşahin; Salim Dönmez; Gözde Yıldırım Çetin; Rıdvan Mercan; Özün Bayındır; Ayşe Çefle; Fatih Yıldız; Ayşe Balkarlı; Levent Kılıç; Necati Çakır; Bünyamin Kısacık; Mustafa Ferhat Öksüz; Veli Çobankara; Ahmet Mesut Onat; Mehmet Sayarlıoğlu; Mehmet Akif Öztürk; Gülsüm Emel Pamuk; Nurullah Akkoç
Journal:  Rheumatol Int       Date:  2016-05-24       Impact factor: 2.631

Review 6.  Gastrointestinal and hepatic manifestations of rheumatoid arthritis.

Authors:  Ellen C Ebert; Klaus D Hagspiel
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.487

7.  Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis.

Authors:  Bożena Targońska-Stępniak; Maria Majdan
Journal:  Mediators Inflamm       Date:  2014-11-27       Impact factor: 4.711

8.  Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Yukiko Nozawa; Hiroe Sato; Takeshi Nakatsue; Daisuke Kobayashi; Yoko Wada; Takako Saeki; Masaaki Nakano; Ichiei Narita
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

9.  Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Authors:  Sinem Nihal Esatoglu; Gulen Hatemi; Serdal Ugurlu; Aycan Gokturk; Koray Tascilar; Huri Ozdogan
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

10.  Prevalence of gastroesophageal reflux disease symptoms and related factors in patients with rheumatoid arthritis.

Authors:  Akihide Nampei; Kenrin Shi; Kosuke Ebina; Tetsuya Tomita; Kazuomi Sugamoto; Hideki Yoshikawa; Makoto Hirao; Jun Hashimoto
Journal:  J Clin Biochem Nutr       Date:  2013-02-06       Impact factor: 3.114
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.